↓ Skip to main content

Interleukin-22 is increased in multiple sclerosis patients and targets astrocytes

Overview of attention for article published in Journal of Neuroinflammation, June 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (73rd percentile)

Mentioned by

twitter
7 tweeters

Readers on

mendeley
89 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Interleukin-22 is increased in multiple sclerosis patients and targets astrocytes
Published in
Journal of Neuroinflammation, June 2015
DOI 10.1186/s12974-015-0335-3
Pubmed ID
Authors

Guillaume Perriard, Amandine Mathias, Lukas Enz, Mathieu Canales, Myriam Schluep, Melanie Gentner, Nicole Schaeren-Wiemers, Renaud A. Du Pasquier

Abstract

Increasing evidences link T helper 17 (Th17) cells with multiple sclerosis (MS). In this context, interleukin-22 (IL-22), a Th17-linked cytokine, has been implicated in blood brain barrier breakdown and lymphocyte infiltration. Furthermore, polymorphism between MS patients and controls has been recently described in the gene coding for IL-22 binding protein (IL-22BP). Here, we aimed to better characterize IL-22 in the context of MS. IL-22 and IL-22BP expressions were assessed by ELISA and qPCR in the following compartments of MS patients and control subjects: (1) the serum, (2) the cerebrospinal fluid, and (3) immune cells of peripheral blood. Identification of the IL-22 receptor subunit, IL-22R1, was performed by immunohistochemistry and immunofluorescence in human brain tissues and human primary astrocytes. The role of IL-22 on human primary astrocytes was evaluated using 7-AAD and annexin V, markers of cell viability and apoptosis, respectively. In a cohort of 141 MS patients and healthy control (HC) subjects, we found that serum levels of IL-22 were significantly higher in relapsing MS patients than in HC but also remitting and progressive MS patients. Monocytes and monocyte-derived dendritic cells contained an enhanced expression of mRNA coding for IL-22BP as compared to HC. Using immunohistochemistry and confocal microscopy, we found that IL-22 and its receptor were detected on astrocytes of brain tissues from both control subjects and MS patients, although in the latter, the expression was higher around blood vessels and in MS plaques. Cytometry-based functional assays revealed that addition of IL-22 improved the survival of human primary astrocytes. Furthermore, tumor necrosis factor α-treated astrocytes had a better long-term survival capacity upon IL-22 co-treatment. This protective effect of IL-22 seemed to be conferred, at least partially, by a decreased apoptosis. We show that (1) there is a dysregulation in the expression of IL-22 and its antagonist, IL-22BP, in MS patients, (2) IL-22 targets specifically astrocytes in the human brain, and (3) this cytokine confers an increased survival of the latter cells.

Twitter Demographics

The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 89 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Italy 1 1%
Unknown 88 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 21 24%
Student > Bachelor 11 12%
Student > Master 10 11%
Researcher 9 10%
Student > Doctoral Student 6 7%
Other 16 18%
Unknown 16 18%
Readers by discipline Count As %
Medicine and Dentistry 17 19%
Biochemistry, Genetics and Molecular Biology 12 13%
Neuroscience 12 13%
Agricultural and Biological Sciences 10 11%
Immunology and Microbiology 10 11%
Other 7 8%
Unknown 21 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 February 2022.
All research outputs
#5,667,639
of 21,358,901 outputs
Outputs from Journal of Neuroinflammation
#977
of 2,455 outputs
Outputs of similar age
#53,738
of 204,680 outputs
Outputs of similar age from Journal of Neuroinflammation
#1
of 1 outputs
Altmetric has tracked 21,358,901 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 2,455 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has gotten more attention than average, scoring higher than 60% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 204,680 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them